7th Eurasian Hematology Oncology Summit


 

2020 Efficacy Data on Targeted Therapies in CLL: Do We Need to Combine Rituximab With Ibrutinib for Better PFS? How Does Venetoclax/Obinutuzumab Affect Survival Rates? What’s the Therapeutic Potential of Acalabrutinib?

78 views
September 28, 2020
0 Comments
Login to view comments. Click here to Login